## Edgar Filing: GENTEX CORP - Form 8-K

GENTEX CORP Form 8-K April 01, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 27, 2019

#### **GENTEX CORPORATION**

(Exact name of registrant as specified in its charter)

Michigan 0-10235 38-2030505 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.)

600 North Centennial

Zeeland, Michigan

Street 49464

(Address of principal

executive offices) (Zip Code)

Registrant's telephone number, including area code: (616) 772-1800

\_\_\_\_\_

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Edgar Filing: GENTEX CORP - Form 8-K

Section 8. Other Events

Item 8.01 Other Events

On March 27, 2019, Steve Downing, President and Chief Executive Officer of Gentex Corporation ("Company"), entered into a stock trading plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 providing for a third-party broker to sell 5,000 shares of common stock of the Company that are issuable upon exercise of the stock options awarded to Mr. Downing in 2012. The shares will be sold under the stock trading plan on the open market over the period of time and according to the other parameters set forth under the stock trading plan. The stock trading plan terminates on October 11, 2019.

On March 27, 2019, Kevin Nash, Vice President of Finance and Chief Financial Officer of the Company, entered into a stock trading plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 providing for a third-party broker to sell shares of common stock of the Company that Mr. Nash may acquire upon the vesting of the 12,000 restricted shares of common stock awarded to Mr. Nash on September 30, 2014, which vesting is anticipated to occur on September 30, 2019. The shares will be sold under the stock trading plan on the open market over the period of time and according to the other parameters set forth under the stock trading plan. The stock trading plan terminates on October 11, 2019.

On March 27, 2019, Scott Ryan, Vice President, General Counsel and Corporate Secretary of the Company, entered into a stock trading plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 providing for a third-party broker to sell 8,320 shares of common stock of the Company that are issuable upon exercise of the stock options awarded to Mr. Ryan in 2014. The shares will be sold under the stock trading plan on the open market over the period of time and according to the other parameters set forth under the stock trading plan. The stock trading plan terminates on January 13, 2020.

Rule 10b5-1 trading plans are permitted under the Company's insider trading policy and other policies, and, to the extent required, transactions under such trading plans will be disclosed publicly through Form 144 and/or Form 4 filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not undertake any obligation to report Rule 10b5-1 plans by officers or directors of the Company in the future, or to report modifications or terminations of any such plans, whether or not any such plans were publicly announced.

# Edgar Filing: GENTEX CORP - Form 8-K

## **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 1, 2019 (Registrant)

**GENTEX CORPORATION** 

By /s/ James Wallace James Wallace

Chairman of the Board of Directors